SWP
CLVS

Stratos Wealth Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Stratos Wealth Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8
Closed – – 2703
2018
Q3 		$0 Buy
+8
New +$310 ﹤0.01% 3076
2018
Q2 		– Sell
-8
Closed – – 2789
2018
Q1 		$0 Buy
+8
New +$467 ﹤0.01% 3263

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Stratos Wealth Partners's CLVS Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 8 shares.

Stratos Wealth Partners first reported a position in CLVS in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 8 Clovis Oncology, Inc. shares in Q4 2018.
  • Stratos Wealth Partners first reported a position in Clovis Oncology, Inc. in Q1 2018 and held it in 2 quarters.
  • Stratos Wealth Partners's Clovis Oncology, Inc. position peaked at $0 in Q3 2018.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.